This may explain why we see reduced efficacy with TNF small molecules when TNFR1 signalling is driven by very high TNF concentrations, although it should be noted that these concentrations typically exceed those measured in patients with autoimmune disease such as rheumatoid arthritis27. This evidence concerns the gene TNFRSF1A and autoimmune disease.